Journal profile · SUBSTANCE ABUSE
Substance Abuse and Rehabilitation
ISSN 1179-8467 · Dove Medical Press · United Kingdom
Substance Abuse and Rehabilitation: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 5.7 (journal website); JCR Q1 (journal website); fully open access; APC about USD 3,565; median 98 days to acceptance (46 articles, last 24 months); acceptance rate 34% (journal website); 24 articles in 2025; indexed in ESCI.
Scope
Aims, scope and focus
Substance Abuse and Rehabilitation is published by Dove Medical Press and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Substance Abuse Treatment and Outcomes, Opioid Use Disorder Treatment and HIV, Drug Use, Sexual Risk, together about 48.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Dr. Rajendra D. Badgaiyan Substance Abuse and Rehabilitation is an international, peer-reviewed, open access online journal publishing original research, case reports, editorials, reviews, commentaries, study designs and methods, statistical designs and study protocols on all areas of addiction and substance abuse and options for treatment and rehabilitation. Substance Abuse and Rehabilitation will no longer consider meta-analyses for publication. Updated 6 August 2025
From the journal's Aims & Scope
Research area (LetPub): SUBSTANCE ABUSE
Editor-in-chief Rajendra D. BadgaiyanPublisher website
Editorial board by country: none in mainland China; most named United States 25, United Kingdom 2, France 2, Canada 2, India 1 (32 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Substance Abuse Treatment and OutcomesMedicine23.7%
- Opioid Use Disorder TreatmentMedicine16.1%
- HIV, Drug Use, Sexual RiskMedicine8.7%
- Prenatal Substance Exposure EffectsMedicine5.1%
- Forensic Toxicology and Drug AnalysisPharmacology, Toxicology and Pharmaceutics4.9%
- Neurotransmitter Receptor Influence on BehaviorNeuroscience4%
- Smoking Behavior and CessationMedicine3.8%
- Pain Management and Opioid UseMedicine3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Substance Abuse | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Substance Abuse | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
JCR / CiteScore quartiles on the journal's website
- JCR Q1 · best quartile · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
ESCIDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 5.7Publisher website ·
- 5-year impact factor (publisher) 2025
- 5.7Publisher website ·
- h-index
- 49OpenAlex ·
- i10-index
- 129OpenAlex ·
- 2-year mean citedness
- 3.6OpenAlex ·
- Self-citation rate
- 6.2%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 23LetPub ·
- Downloads per year (publisher)
- 53,124Publisher website ·
Articles by year OpenAlex count · 240 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 19 | 19 | 15 |
| 2025 | 24 | 24 | 78 |
| 2024 | 19 | 19 | 130 |
| 2023 | 16 | 16 | 221 |
| 2022 | 12 | 12 | 502 |
| 2021 | 11 | 11 | 322 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
98 daysMedian, submission to acceptance · P25–P75 80 days – 123 days
- Acceptance to online
- median 14 days (46 articles)
- Submission to online
- median 113 days
- Sample
- 46 articles with submission and acceptance dates (47 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 34%Publisher website ·
- Desk decision
- 31 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,565 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,320 | — | — | |
| LetPub | USD 2,990 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted5
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- hypothesisHypothesisLength not stated
- original researchOriginal ResearchLength not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- short reportShort ReportLength not stated
Policy excerpts from the journal's websitePeer review
- Peer review
COPE member Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 1179-8467
- Official links
- Journal homepage ↗DOAJ
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Substance Abuse and Rehabilitation
What CAS zone is Substance Abuse and Rehabilitation in?
In the 2025 upgraded edition of the CAS Journal Ranking, Substance Abuse and Rehabilitation is in Zone 3 of Medicine, and in Zone 3 of the minor category Substance Abuse. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Substance Abuse and Rehabilitation?
The journal's website gives an impact factor of 5.7 (2025); this is the journal's own figure, as LetPub lists none for it; h-index 49.
How long does peer review take at Substance Abuse and Rehabilitation?
Based on the dates recorded on 46 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 98 days (interquartile range 80–123 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 34%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Substance Abuse and Rehabilitation in?
The journal's website gives JCR Q1 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Where are the editorial board members of Substance Abuse and Rehabilitation based?
Of the 32 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (25), United Kingdom (2) and France (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Substance Abuse and Rehabilitation?
According to LetPub and DOAJ records, Substance Abuse and Rehabilitation is indexed in ESCI and DOAJ.
Is Substance Abuse and Rehabilitation open access, and what is the APC?
Substance Abuse and Rehabilitation is a fully open-access journal. APC about USD 3,565.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .